Hot Features
Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD)... Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.38 | -3.68574199806 | 10.31 | 10.72 | 8.78 | 1638379 | 9.69405508 | CS |
| 4 | -2.34 | -19.0709046455 | 12.27 | 13.39 | 8.78 | 1214384 | 10.99833579 | CS |
| 12 | -0.41 | -3.96518375242 | 10.34 | 13.665 | 8.78 | 1254188 | 11.45015199 | CS |
| 26 | -4.76 | -32.4029952349 | 14.69 | 18.31 | 8.78 | 1173499 | 12.73277063 | CS |
| 52 | 5.28 | 113.548387097 | 4.65 | 18.31 | 4.4706 | 1440669 | 11.43246849 | CS |
| 156 | -1.64 | -14.1745894555 | 11.57 | 19.675 | 2.21 | 1058607 | 10.22996949 | CS |
| 260 | -23.6 | -70.3847300925 | 33.53 | 37.17 | 2.21 | 727265 | 10.57526908 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.